Alex Zhavoronkov, PHD, Founder and CEO of Insilico Medicine, shares his latest clinical research results, discusses Insilico's upcoming products, and explains his company's use of generative AI in shaping the future of medicine.
Alex Zhavoronkov, PhD, Chairman and CEO of Insilico Medicine, discusses how generative AI is transforming and accelerating drug discovery, particularly for diseases related to aging. He also shares exciting news about Insilico Medicine's latest deal with Exelixis to develop novel drugs for BRCA-mutant tumors found in breast, ovarian, pancreatic and prostate cancers.
Biotech Insilico Medicine aims to transform drug discovery and development using generative AI. that discovers novel targets, generates new molecules, and predicts clinical trial success.
